Form 4 for PTGX Protagonist Therapeutics, Inc
Accepted 2024-01-04 00:00:00 ET · period of report 2023-11-15 · accession 0001104659-24-001490 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-04 | 2024-01-02 | PTGX | MOLINA ARTURO MD | Chief Medical Off | A - Grant | $0.00 | +26.2K | 48.8K | +117% | $0 |
| D | 2024-01-04 | 2023-11-15 | PTGX | MOLINA ARTURO MD | Chief Medical Off | S - Sale | $16.24 | -1,848 | 22.5K | -8% | -$30.0K |
| D | 2024-01-04 | 2024-01-02 | PTGX | MOLINA ARTURO MD | Chief Medical Off | A - Grant | $0.00 | +97.5K | 97.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-02 | A | A | 26,250 | $0.00 | 48,777 | D | — | — | (F2) Represents grant of restricted stock units payable solely in common stock that will vest in three equal annual installments on January 15, 2025, 2026 and 2027, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |
| 2 | Common | Common Stock | 2023-11-15 | S | D | 1,848 | $16.24 | 22,527 | D | — | — | (F1) Sale of shares to cover tax withholding obligation incurred upon settlement of restricted stock units. |
| 3 | Derivative | Stock Option (right to buy) | 2024-01-02 | A | A | 97,500 | $0.00 | 97,500 | D | $23.42 · — to 2034-01-02 | 97,500 Common Stock | (F3) The stock option vests in 48 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. |